Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Protagonist Therapeutics Inc (NQ: PTGX )

20.91 -0.04 (-0.19%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Protagonist Therapeutics Inc

< Previous 1 2 Next >
Protagonist Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-to-Head Comparisons with Deucravacitinib
Via ACCESSWIRE
Protagonist Therapeutics Reports Granting of Inducement Awards
Via ACCESSWIRE
Protagonist Therapeutics Ranked in the Top 3% of Fastest-Growing Companies in North America on the 2023 Deloitte Technology Fast 500(TM)
Via ACCESSWIRE
Protagonist Therapeutics Announces Abstracts Selected for Oral and Poster Presentations at the American Society of Hematology 2023 Annual Meeting
Via ACCESSWIRE
Protagonist Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Protagonist Announces Achievement of $50M Milestone Event After Third Patient is Dosed in Phase 3 Study of JNJ-2113 in Moderate-to-Severe Psoriasis
Via ACCESSWIRE
Protagonist Announces Advancement of JNJ-2113 Across Multiple Indications
Via ACCESSWIRE
Protagonist Receives $34 Million from Warrant Exercises
Via ACCESSWIRE
Protagonist Therapeutics Inc. (NASDAQ: PTGX) is a Stock Spotlight on 6/1
Via Investor Brand Network
Protagonist Therapeutics to Participate in Upcoming Investor Conferences
Via ACCESSWIRE
Protagonist Therapeutics Announces Appointment of Daniel Swisher to Its Board of Directors
Via ACCESSWIRE
Protagonist Therapeutics Reports Granting of Inducement Award
Via ACCESSWIRE
Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 22, 2023 – USA News Group – Despite the potential federal funding challenges due to the recent debt ceiling deal,... 
Via FinancialNewsMedia
Protagonist Therapeutics to Present at Upcoming Investor Conferences
Via ACCESSWIRE
Protagonist Therapeutics Reports Granting of Inducement Award
Via ACCESSWIRE
Protagonist Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Protagonist Therapeutics Reports Granting of Inducement Award
Via ACCESSWIRE
Protagonist Therapeutics Announces Positive Topline Results with JNJ-2113, the First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis
Via ACCESSWIRE
Are (More) Big Gains Ahead for This Small Cap Biotech Stock?
With Biomea Fusion's share price nearly halved recently, oversold conditions seem to be setting in. This could be an opportunity for small cap growth investors. 
Via MarketBeat
Topics Initial Public Offering
Exposures Securities Market
Clinical Response and Durability of Response of Rusfertide (PTG-300) in Polycythemia Vera Featured Today at EHA Press Briefing; Protagonist Therapeutics Plans a Follow-on Two-Year Extension Study to Enable Further Evaluation of the Long-Term Effects of
Via ACCESSWIRE
Protagonist Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at 2023 European Hematology Association (EHA) Congress
Via ACCESSWIRE
Protagonist Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
Via ACCESSWIRE
Protagonist Therapeutics Announces Pricing of $100 Million Public Offering of Shares of Common Stock
Via ACCESSWIRE
Protagonist Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
Via ACCESSWIRE
Protagonist Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera
Via ACCESSWIRE
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shareholder Alert: Investigation over Possible Wrongdoing
San Diego, CA -- (SBWIRE) -- 06/27/2022 -- Certain directors of Protagonist Therapeutics, Inc. are under investigation over potential breaches of fiduciary duties. 
Via SBWire
Investigation Reminder: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Regulatory Compliance
Exposures Legal Product Safety Regulatory
Investigation Alert: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Regulatory Compliance
Exposures Legal Product Safety Regulatory
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.